1. Signaling Pathways
  2. Cell Cycle/DNA Damage
    Metabolic Enzyme/Protease
    Vitamin D Related/Nuclear Receptor
  3. PPAR

PPAR

PPAR

Peroxisome proliferator-activated receptors

PPARs (Peroxisome proliferator-activated receptors) are ligand-activated transcription factors of nuclear hormone receptor superfamily comprising of the following three subtypes: PPARα, PPARγ, and PPARβ/δ. PPARs play essential roles in the regulation of cellular differentiation, development, and metabolism (carbohydrate, lipid, protein), and tumorigenesis of higher organisms. All PPARs heterodimerize with the retinoid X receptor (RXR) and bind to specific regions on the DNA of target genes. Activation of PPAR-α reduces triglyceride level and is involved in regulation of energy homeostasis. Activation of PPAR-γ enhances glucose metabolism, whereas activation of PPAR-β/δ enhances fatty acids metabolism.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-16737
    Elafibranor
    Agonist 99.32%
    Elafibranor (GFT505) is a PPARα agonist with EC50s of 45 and 175 nM, respectively. Elafibranor can be used for the study of primary biliary cholangitis.
    Elafibranor
  • HY-129993
    Gemfibrozil 1-O-β-glucuronide
    Inhibitor 99.88%
    Gemfibrozil 1-O-β-Glucuronide, a metabolite of Gemfibrozil (CI-719; HY-B0258), is a potent and competitive P450 (CYP) isoform CYP2C8 inhibitor with an IC50 of 4.07 μM.
    Gemfibrozil 1-O-β-glucuronide
  • HY-15655
    GW1929
    Agonist 99.93%
    GW 1929 is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pKi of 8.84 for human PPAR-γ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW 1929 (hydrochloride) has antidiabetic efficacy and neuroprotective potential.
    GW1929
  • HY-N0292
    Oleuropein
    Inhibitor 99.05%
    Oleuropein, found in olive leaves and oil, exerts antioxidant, anti-inflammatory and anti-atherogenic effects through direct inhibition of PPARγ transcriptional activity. Oleuropein induces apoptosis in breast cancer cells via the p53-dependent pathway and through the regulation of Bax and Bcl2 genes. Oleuropein also inhibits aromatase.
    Oleuropein
  • HY-B0637
    Bezafibrate
    Agonist 99.83%
    Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
    Bezafibrate
  • HY-N0393
    Glabridin
    Activator 99.98%
    Glabridin is a natural isoflavan from Glycyrrhiza glabra L., binds to and activates PPARγ, with an EC50 of 6115 nM. Glabridin exhibits antioxidant, anti-bacterial, anti-nephritic, anti-diabetic, anti-fungal, antitumor, anti-inflammatory, antiosteoporotic, cardiovascular protective, neuroprotective and radical scavenging activities.
    Glabridin
  • HY-14601
    Pioglitazone hydrochloride
    Agonist 99.97%
    Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC50s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
    Pioglitazone hydrochloride
  • HY-N2302
    Fucoxanthin
    Inhibitor 98.99%
    Fucoxanthin (all-trans-Fucoxanthin) is a marine carotenoid and shows anti-obesity, anti-diabetic, anti-oxidant, anti-inflammatory and anticancer activities.
    Fucoxanthin
  • HY-13928
    GW0742
    Agonist 99.94%
    GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.
    GW0742
  • HY-N0163
    Magnolol
    Agonist 99.84%
    Magnolol, a natural lignan isolated from the stem bark of Magnolia officinalis, is a dual agonist of both RXRα and PPARγ, with EC50 values of 10.4 µM and 17.7 µM, respectively.
    Magnolol
  • HY-107542
    Oleoylethanolamide
    Agonist 99.94%
    Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.
    Oleoylethanolamide
  • HY-14166
    MK-886
    Antagonist 99.77%
    MK-886 (L 663536) is a potent, cell-permeable and orally active FLAP (IC50 of 30 nM) and leukotriene biosynthesis (IC50s of 3 nM and 1.1 μM in intact leukocytes and human whole blood, respectively) inhibitor. MK-886 is also a non-competitive PPARα antagonist and can induce apoptosis.
    MK-886
  • HY-145804
    Palacaparib
    Inhibitor 99.11%
    AZD-9574 is a potent and brain penetrant PARP1 inhibitor and shows >8000-fold selectivity for PARP1 compared to PARP2/3/5a/6. AZD-9574 acts by selectively inhibiting and trapping PARP1 at the sites of SSBs. AZD-9574 is an anti-cancer agent and can be used for HRD+?breast cancer and advanced solid malignancies research.
    Palacaparib
  • HY-15577
    GSK3787
    Antagonist 98.03%
    GSK3787 is a selective and irreversible peroxisome proliferator-activated receptor δ (PPARδ) antagonist with pIC50 of 6.6.
    GSK3787
  • HY-15721
    FH535
    Inhibitor 98.72%
    FH535 is an inhibitor of Wnt/β-catenin and PPAR with anti-tumor activities.
    FH535
  • HY-B0258
    Gemfibrozil
    Activator 99.91%
    Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.
    Gemfibrozil
  • HY-12377
    GSK0660
    Antagonist 99.19%
    GSK0660 is a potent PPARβ antagonist with an IC50 of 155 nM.
    GSK0660
  • HY-113081
    1-Methyladenosine
    Inducer 99.21%
    1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis.
    1-Methyladenosine
  • HY-N1472
    Levistolide A
    Inducer 99.26%
    Levistolide A is an apoptosis inducer and a PEDV virus inhibitor. Levistolide A can induce apoptosis in colon cancer cells and suppress the replication of porcine epidemic diarrhea virus (PEDV) by promoting ROS generation. Levistolide A activates peroxisome proliferator-activated receptor γ (PPARγ) in N2a/APP695swe cells and reduces excessive phosphorylation of tau through the GSK3α/β pathway, improving symptoms in Alzheimer’s mice. Levistolide A improves kidney damage in 5/6 nephrectomy (Nx) mice by inhibiting the RAS,TGF-β1/Smad, and MAPK pathways.
    Levistolide A
  • HY-14600
    Rosiglitazone maleate
    Agonist 99.88%
    Rosiglitazone maleate (BRL 49653C) is a potent and selective activator of PPARγ, with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively, and a Kd of appr 40 nM for PPARγ; Rosiglitazone maleate is also an modulator of TRP channels, inhibits TRP melastatin 2 (TRPM2), TRPM3 and activates TRP canonical 5 (TRPC5).
    Rosiglitazone maleate
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

PPARα

PPARβ/δ

PPARγ

PPAR

PPARδ

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

PPAR Inducers, Ligands, Inhibitors, Agonists, Antagonists, Activators & Modulators
Product NamePPARαPPARβ/δPPARγPPARPPARδPurity    
Retinoic acid
PPARα, Kd: 103 nM
PPARα, IC50: 14 nM
PPARβ/δ, Kd: 17 nM
RARβ, IC50: 14 nM
PPARγ, Kd: 178 nM
PPARγ, IC50: 14 nM
  99.81%
Rosiglitazone  
PPARγ, Kd: 40 nM
PPARγ, EC50: 60 nM
  99.94%
GW9662
PPARα, IC50: 32 nM
PPARδ, IC50: 2000 nM
PPARγ, IC50: 3.3 nM
  99.79%
Pioglitazone
hPPARα, EC50: 100 μM
mouse PPARα, EC50: 100 μM
hPPARδ, EC50: 43 μM
hPPARγ, EC50: 0.93 μM
mouse PPARγ, EC50: 0.99 μM
  99.89%
Fenofibrate
PPARα, IC50: 30 μM
    99.97%
Anandamide   
PPAR
 ≥99.0%
1,1'-(Azodicarbonyl)-dipiperidine
PPARα
 
PPAR-γ
 
PPARδ
GW6471
PPARα
    99.64%
5-Aminosalicylic Acid  
PPARγ
  99.82%
Pirinixic acid
PPARα, EC50: 0.63 μM
 
PPARγ, EC50: 32 μM
  98.81%
Troglitazone  
PPARγ, EC50: 550 nM (Human PPARγ)
  99.78%
T0070907
PPARα, Ki: 0.85 μM
PPARδ, Ki: 1.8 μM
PPARγ, Ki: 1 nM
  99.98%
Astaxanthin  
PPARγ
  ≥98.0%
Daidzein
PPAR-α
 
PPAR-γ
  99.72%
Icariin
PPARα
    99.06%
GW7647
PPARα, EC50: 6 nM (Human PPARα)
PPARδ, EC50: 6.2 μM (Human PPARδ)
PPARγ, EC50: 1.1 μM (Human PPARγ)
  99.45%
GW 501516 
PPARδ, EC50: 1.1 nM
   99.43%
Elafibranor
PPAR-α, EC50: 45 nM
PPAR-δ, EC50: 175 nM
   99.32%
GW1929  
PPAR-γ, pEC50: 8.56 (Human PPAR-γ)
  99.93%
Oleuropein  
PPARγ
  99.05%
Bezafibrate
hPPARα, EC50: 50 μM
hPPARδ, EC50: 20 μM
hPPARγ, EC50: 60 μM
  99.83%
Glabridin  
PPARγ, EC50: 6.1 μM
  99.98%
Pioglitazone hydrochloride
PPARα, EC50: 0.93 μM (Human PPARα)
PPARδ, EC50: 0.01 μM (Human PPARδ)
PPARγ, EC50: 43 μM (Human PPARγ)
  99.97%
Fucoxanthin
PPARα
 
PPARγ
  98.99%
GW0742
PPARα, EC50: 1.1 μM
PPARδ, EC50: 1 nM
PPARγ, EC50: 2 μM
  99.94%
Magnolol  
PPARγ, EC50: 17.7 μM
  99.84%
Oleoylethanolamide
PPAR-α
    99.94%
Palacaparib   
PPAR
 99.11%
GSK3787 
PPARδ, pIC50: 6.6 nM
   98.03%
FH535   
PPAR
 98.72%
Gemfibrozil
PPAR-α
    99.91%
GSK0660 
PPARβ/δ, IC50: 155 nM
   99.19%
1-Methyladenosine  
PPAR-γ
  99.21%
Rosiglitazone maleate  
PPARγ1, EC50: 30 nM
PPARγ2, EC50: 100 nM
  99.88%
CDDO-Im
PPARα, Ki: 232 nM
 
PPARγ, Ki: 344 nM
  98.47%
Palmitelaidic Acid
PPARα
    ≥99.0%
Pemafibrate
h-PPARα, EC50: 1 nM
PPARδ, EC50: 1.58 μM
h-PPARγ, EC50: 1.1 μM
  99.85%
Candesartan  
PPAR-γ
  98.03%
1,2-DLPC
PPARα
    ≥98.0%
Retinoic acid (Standard)
PPARα
PPARβ/δ
RARβ
PPARγ
  
Eupatilin
PPARα
    98.90%
FX-909  
PPARγ
  98.80%
Chiglitazar
PPARα, EC50: 1.8 μM
PPARδ, EC50: 1.7 μM
PPARγ, EC50: 0.08 μM
  98.81%
Bavachinin
PPARα, IC50: 21.043 μM
PPARδ, IC50: 12.819 μM
PPAR-γ, IC50: 0.622 μM
  99.95%
Fenofibric acid
PPARα, EC50: 22.4 μM
PPARδ, EC50: 1.06 μM
PPARγ, EC50: 1.47 μM
  99.94%
Seladelpar
PPAR-α, EC50: 1600 nM
PPAR-δ, EC50: 2 nM
   99.75%
15-Deoxy-Δ-12,14-prostaglandin J2  
PPARγ, EC50: 2 μM
  ≥99.0%
Alpinetin  
PPAR-γ
  99.51%
Fmoc-leucine  
PPARγ
  99.91%
Rosiglitazone hydrochloride  
PPARγ, EC50: 60 nM
PPARγ, Kd: 40 nM
  99.31%
Seladelpar sodium salt 
PPAR-δ, EC50: 2 nM
   98.77%
SR1664  
PPAR-γ, IC50: 80 nM
  ≥98.0%
Agrimol B  
PPARγ
  99.75%
Saroglitazar
PPARα, EC50: 0.65 pM (HepG2 cell)
 
PPARγ, EC50: 3 nM (HepG2 cell)
  99.10%
Clofibrate
PPARα, EC50: 50 μM
 
PPARγ, EC50: 500 μM
  99.61%
Ginsenoside Rh1  
PPAR-γ
  ≥98.0%
Ophiopogonin D
PPARα
    99.54%
Bilobetin
PPARα
    99.39%
Avicularin  
PPARγ
  99.80%
Oroxin A  
PPARγ
  99.76%
Cefminox sodium  
PPARγ
  99.83%
Norathyriol
PPARα, IC50: 92.8 μM
PPARβ, IC50: 102.4 μM
PPARγ, IC50: 153.5 μM
  99.83%
DG172 dihydrochloride 
PPARβ/δ, IC50: 27 nM
   99.35%
Ertiprotafib
PPARα, EC50: ~1 μM
PPARβ, EC50: ~1 μM
   98.86%
4-O-Methyl honokiol  
PPARγ
  98.18%
NXT629
hPPARα, IC50: 77 nM
hPPARδ, IC50: 6 μM
hPPARγ, IC50: 15 μM
  99.07%
Mifobate  
PPARγ, IC50: 140 μM
  99.10%
Hexadecanamide
PPARα
    
MTX-531  
PPARγ, EC50: 3.4 μM
  99.87%
Ciprofibrate
PPARα
    99.93%
PPARα/γ agonist 1
PPARα, EC50: 28 nM
 
PPARγ, EC50: 69 nM
  99.68%
BMS-687453
PPARα, IC50: 260 nM (Human PPARα)
    99.31%
BAY-4931  
PPAR-γ, IC50: 0.17 nM (RT112-FABP4-NLucP cellular reporter assay)
mouse PPARγ, IC50: 0.14 nM (GAL4-NHR-LBD one hybrid reporter assay )
hPPARγ, IC50: 0.40 nM (GAL4-NHR-LBD one hybrid reporter assay )
  98.83%
Licarin B  
PPARγ
  99.93%
AMG131  
PPARγ
  99.64%
Glabrone  
PPAR-γ
  99.08%
L-165041 
PPARδ, Ki: 6 nM
PPARγ, Ki: 730 nM
  99.67%
Leriglitazone hydrochloride  
PPAR-γ, EC50: 9 μM
  99.64%
Gypenoside XLIX
PPAR-α
    99.15%
Raspberry ketone
PPAR-α
    99.91%
PPARγ-IN-2  
PPARγ
  99.57%
GSK1820795A  
hPPARγ, EC50: 0.25 μM
mouse PPARγ, EC50: 0.27 μM
  99.76%
Saroglitazar magnesium
PPARα, EC50: 0.65 pM (HepG2 cell)
 
PPARγ, EC50: 3 nM (HepG2 cell)
  98.85%
Darglitazone  
PPAR-γ
  99.19%
Balaglitazone  
PPARγ, EC50: 351 nM (Human PPARγ)
  99.74%
Etrinabdione  
PPARγ
  99.16%
HWL-088 
PPARδ, EC50: 570.9 nM
   98.61%
Leriglitazone  
PPAR-γ, EC50: 9 μM
  99.23%
Indeglitazar
PPARα
PPARδ
PPARγ
  99.11%
BAY-0069  
hPPARγ, IC50: 6.3 nM
mouse PPARγ, IC50: 24 nM
  98.07%
Daidzein (Standard)
PPAR-α
 
PPAR-γ
  99.46%
Adelmidrol  
PPARγ
  ≥98.0%
Drupanin
PPARα, EC50: 39.0 μM
 
PPARγ, EC50: 14.6 μM
  98.05%
LT175
hPPARα, EC50: 0.22 μM
mPPARα, EC50: 0.26 μM
 
hPPARγ, EC50: 0.48 μM
  99.79%
SR 16832  
PPARγ
  99.89%
GW 9578
mouse PPARα, EC50: 5 nM
h-PPARα, EC50: 50 nM
    99.6%
CUDA
PPARα
    ≥98.0%
Aleglitazar
PPARα, IC50: 38 nM
 
PPARγ, IC50: 19 nM
  99.74%
FTX-6746  
PPARγ
  98.68%
Inolitazone dihydrochloride  
PPARγ
  98.86%
(10E,12Z)-Octadeca-10,12-dienoic acid
PPARα
    99.10%
CP-868388 free base
hPPARα, Ki: 10.8 nM
 
hPPARγ, Ki: 3.47 μM
  99.66%
Lobeglitazone
PPARα, EC50: 546.3 nM
 
PPARγ, EC50: 137.4 nM
  
Methyl oleanonate  
PPARγ
  99.81%
Falcarindiol  
PPARγ
  99.48%
Azemiglitazone potassium  
PPAR-γ, IC50: 18.25 μM
  99.53%
F44-A13
PPARα
PPARβ
   
Fenofibrate (Standard)
PPARα
    99.91%
FK614  
PPAR-γ
  99.97%
Lobeglitazone sulfate
PPARα, EC50: 546.3 nM
 
PPARγ, EC50: 137.4 nM
  99.63%
Netoglitazone
PPARα
 
PPARγ
  99.88%
Edaglitazone
PPARα, EC50: 1053 nM
 
PPARγ, EC50: 35.6 nM
  99.58%
Fenofibric acid (Standard)
PPARα
PPARδ
PPARγ
  99.16%
ST247 
PPARβ/δ
   99.88%
25-Hydroxytachysterol3  
PPARγ
  98.89%
1-O-Hexadecylglycerol  
PPAR-γ
  ≥98.0%
SR 11023  
PPARγ, IC50: 108 nM
  99.55%
H-​Trp-​Glu-​OH  
PPARγ, Kd: 8 μM
  99.95%
PPARγ phosphorylation inhibitor 1  
PPARγ, IC50: 24 nM
  99.81%
Arhalofenate  
PPAR-γ
  
BAY-5094  
PPAR-γ
  98.04%
MA-0204 
PPARδ, EC50: 0.4 nM (in human)
PPARδ, EC50: 7.9 nM (in mouse)
PPARδ, EC50: 10 nM (in rat)
   99.31%
MRL-24  
PPARγ
  
10-Nitrolinoleic acid  
PPARγ, IC50: 0.22 μM
  
Clofibrate (Standard)
PPARα
 
PPARγ
  98.09%
SDPC  
PPARγ
  
Angeloylgomisin H  
PPAR-γ
  99.79%
Gemfibrozil (Standard)
PPAR-α
    99.90%
PPARγ agonist 14  
PPARγ, EC50: 2.4 μM
  
13-Oxo-9E,11E-octadecadienoic acid
PPARα
    
GSK376501A  
PPARγ
  99.06%
(±)4-HDHA  
PPARγ
  99.05%
PPAR agonist 1
PPARα
 
PPARγ
  98.39%
Rosiglitazone potassium  
PPARγ, Kd: 40 nM
PPARγ, EC50: 60 nM
  
Pparδ agonist 5    
PPARδ, EC50: 0.335 μM
Seladelpar Lysine dihydrate    
PPARδ, EC50: 2 nM
≥98.0%
Pioglitazone potassium
hPPARα, EC50: 100 μM
mouse PPARα, EC50: 100 μM
hPPARδ, EC50: 43 μM
mouse PPARγ, EC50: 0.99 μM
h-PPARγ, EC50: 0.93 μM
  
9(10)-Nitrooleate
PPARα
PPARβ/δ
PPARγ
  
PPARα/δ agonist 2
PPARα, EC50: 3255 nM
PPARβ/δ, EC50: 1475 nM
   
Ciprofibrate impurity A
PPARα
    
BMS711939
hPPARα, IC50: 4 nM
 
hPPARγ, IC50: 4.5 μM
  
MBX-102 acid  
PPARγ
  
Tibesaikosaponin V  
PPARγ
  
PPARγ-IN-3  
PPARγ
  
Gancaonin L  
PPAR-γ
  
PPAR agonist 4
PPARα, EC50: 0.7 μM
 
PPARγ, EC50: 1.8 μM
 
PPARδ, EC50: 0.7 μM
LJ570
PPARα, EC50: 1.05 μM
 
PPARγ, EC50: 0.12 μM
  
PPARγ/δ modulator 2  
PPARγ
 
PPARδ
Caulophyllogenin  
PPARγ, EC50: 12.6 μM
  
Pparδ agonist 1 
PPARδ, EC50: 5.06 nM
   
Darglitazone Sodium  
PPAR-γ
  
Rac-Pemafibrate
h-PPARα, EC50: 1 nM
h-PPARδ, EC50: 1.7 μM
   
PPARγ/δ modulator 1  
PPARγ, Ki: 5.31 μM
 
PPARδ, Ki: 14.4 nM
Imiglitazar
PPARα, EC50: 67 nM
 
PPARγ1, EC50: 31 nM
  
GW1929 hydrochloride  
hPPARγ, pKi: 8.84
  
Fonadelpar 
PPARδ
   
Icariin (Standard)
PPARα
    
Cinoxate  
PPARγ, Ki: 18 μM
  
Cevoglitazar
PPARα
 
PPARγ
  
Pparδ agonist 2 
PPARδ
   
PPARγ agonist 16  
PPAR-γ, IC50: 1790 nM
  
Apo-12'-lycopenal  
PPAR-γ
  
KD-3010 
PPARδ
   
PPARγ agonist 8  
PPARγ
  
Eupatilin (Standard)
PPARα
    
DS-6930  
PPARγ, EC50: 41 nM
  
Romazarit
PPARα
    
Ginsenoside Rh1 (Standard)  
PPAR-γ
  
PPARα/δ agonist 1
PPARα, EC50: 7 nM
 
PPARγ, EC50: 1316.1 nM
 
PPARδ, EC50: 8.4 nM
SR2595  
PPARγ, IC50: 30 nM
  
PPARδ agonist 10    
PPARδ, EC50: 0.053 μM (hPPARδ)
PPARδ, EC50: 0.30 μM (mPPARδ)
PPARγ modulator-1  
PPAR-γ
  
L-783483    
PPARδ
PPARδ agonist 11
hPPARα, EC50: 8 μM
hPPARδ, EC50: 0.02 μM
   
PPARγ agonist 2  
PPARγ
  
PPARα/δ agonist 3
PPARα, IC50: 5.6 nM
 
PPARγ, IC50: 1278 nM
 
PPARδ, IC50: 3.4 nM
CAY10410  
PPARγ
  
Mesalamine impurity P   
PPAR
 
15-LOX-IN-2  
PPARγ
  
GW7845  
PPARγ
  
PPAR agonist 5
PPARα, EC50: 3.20 μM
PPARβ/δ, EC50: 1.51 μM
PPARγ, EC50: 1.92 μM
  
ZLY06  
PPARγ, IC50: 237 nM
 
PPARδ, IC50: 341 nM
PPARα agonist 1
hPPARα
    
4,5-DiHDPA lactone  
PPARγ
  
Amezalpat
PPARα, IC50: 58 nM
    
E0924G 
PPARδ, EC50: 2.82 μM
   
PPARγ-IN-5  
PPARγ
  
Glabridin (Standard)  
PPARγ
  
YGT-31  
PPARγ, IC50: 1.72 μM
PPARγ, Ki: 0.62 μM
  
PPARγ/GR modulator 1  
PPARγ, Ki: 3.3 μM
  
Avicularin (Standard)  
PPARγ
  
PPARα/γ agonist 2
PPARα, EC50: 0.95 μM
 
PPARγ, EC50: 0.91 μM
  
SKLB102  
PPAR-γ
  
PPARα/γ agonist 4
PPARα
 
PPAR-γ
  
PPARγ modulator-2  
PPARγ, IC50: 41 nM
  
DSO-5a  
PPARγ
  
Chiglitazar sodium
PPARα, EC50: 1.8 μM
PPAR-δ, EC50: 1.7 μM
PPAR-γ, EC50: 0.08 μM
  
Elaidyl-sulfamide
PPARα
    
Rosiglitazone sodium  
PPARγ1, EC50: 30 nM
PPARγ2, EC50: 100 nM
  
Prostaglandin A3  
PPAR-γ, Ki: 188 μM
  
PT-S58 
PPARβ/δ, IC50: 98 nM
   
Prostaglandin B3  
PPARγ
  
Sitofibrate
PPAR-α
    
AZD4619
PPARα
    
T2384  
PPARγ
  
SR-1903  
PPARγ, IC50: 209 nM
  
Inolitazone  
PPARγ
  
17-Oxo-7(Z),10(Z),13(Z),15(E),19(Z)-docosapentaenoic acid  
PPARγ
  
GW 2433
PPARα
   
PPARδ
ZINC17167211
PPAR-α, EC50: 0.16 nM
    
TZD18
hPPARα, IC50: 0.028 μM
 
hPPARγ, IC50: 0.057 μM
 
PPARδ, IC50: >10 μM
AVE-8134
PPARα, EC50: 100 nM (Human PPARα)
    
GW409544
PPARα, EC50: 2.3 nM
 
PPAR-γ, EC50: 0.28 nM
  
CLX-0921  
PPARγ, IC50: 1.54 μM
  
N-Octadecyl-N'-propyl-sulfamide
PPARα
    
NS-220
PPARα, EC50: 19 nM
 
PPARγ, EC50: 9.6 μM
 
PPARδ, EC50: >1 mM
PPARα agonist 2
PPARα, EC50: 37 nM
    
PPARα-MO-1
PPARα